Previous Close | 5.48 |
Open | 5.54 |
Bid | 5.31 x 1000 |
Ask | 5.33 x 900 |
Day's Range | 5.30 - 5.74 |
52 Week Range | 2.10 - 13.00 |
Volume | 461,349 |
Avg. Volume | 652,288 |
Market Cap | 71.806M |
Beta (5Y Monthly) | 0.86 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.37 |
Earnings Date | Mar 23, 2021 - Mar 29, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 20.00 |
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael W. Nall has issued the following letter to stockholders:
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael Nall will present at the H.C. Wainwright Virtual BioConnect Conference being held January 11-14, 2021. The presentation can be accessed on the Investor Relations section of the Biocept website beginning on January 11, 2021 at 6:00 a.m. Eastern time.
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, today announced that it has granted inducement stock options to purchase an aggregate of 83,120 shares of its common stock to 14 new employees. These inducement stock options have a grant date of December 31, 2020, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).